Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers

A. Tripodi, M. Moia, B. Bottasso, P. M. Tenconi, F. Gianese, P. M. Mannucci

Research output: Contribution to journalArticle

Abstract

Eight healthy volunteers were given single subcutaneous doses of dermatan sulfate (DS, 100, 200 and 400 mg), heparin (5,000 IU) and placebo in random order. Wash-out between treatments was > 10 days. Serial blood samples were taken before and up to 24 hours after treatment to measure coagulation and fibrinolytic parameters. Thrombin generation was significantly inhibited by DS and heparin as compared to placebo. The effect of DS was dose-dependent. Peak inhibition after 200 mg DS was comparable to that of 5,000 IU heparin, but lasted longer. A small, bordeline significant prolongation of APTT was observed after 400 mg DS and heparin. The changes in PAI and fibrinolytic activities were those of the circadian variation. No changes were seen in the other parameters tested. In conclusion, single s.c. doses of DS (200, or 400 mg) inhibit ex vivo thrombin generation equally or more than 5,000 IU heparin and for a longer time. The effect of both treatments on fibrinolysis is negligible.

Original languageEnglish
Pages (from-to)663-672
Number of pages10
JournalThrombosis Research
Volume62
Issue number6
DOIs
Publication statusPublished - Jun 15 1991

Fingerprint

Dermatan Sulfate
Heparin
Healthy Volunteers
Thrombin
Placebos
Fibrinolysis
Therapeutics

Keywords

  • coagulation
  • Dermatan sulfate
  • fibrinolysis
  • heparin
  • pharmacodynamics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. / Tripodi, A.; Moia, M.; Bottasso, B.; Tenconi, P. M.; Gianese, F.; Mannucci, P. M.

In: Thrombosis Research, Vol. 62, No. 6, 15.06.1991, p. 663-672.

Research output: Contribution to journalArticle

@article{d62c4485839743c3b788e7608ead8362,
title = "Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers",
abstract = "Eight healthy volunteers were given single subcutaneous doses of dermatan sulfate (DS, 100, 200 and 400 mg), heparin (5,000 IU) and placebo in random order. Wash-out between treatments was > 10 days. Serial blood samples were taken before and up to 24 hours after treatment to measure coagulation and fibrinolytic parameters. Thrombin generation was significantly inhibited by DS and heparin as compared to placebo. The effect of DS was dose-dependent. Peak inhibition after 200 mg DS was comparable to that of 5,000 IU heparin, but lasted longer. A small, bordeline significant prolongation of APTT was observed after 400 mg DS and heparin. The changes in PAI and fibrinolytic activities were those of the circadian variation. No changes were seen in the other parameters tested. In conclusion, single s.c. doses of DS (200, or 400 mg) inhibit ex vivo thrombin generation equally or more than 5,000 IU heparin and for a longer time. The effect of both treatments on fibrinolysis is negligible.",
keywords = "coagulation, Dermatan sulfate, fibrinolysis, heparin, pharmacodynamics",
author = "A. Tripodi and M. Moia and B. Bottasso and Tenconi, {P. M.} and F. Gianese and Mannucci, {P. M.}",
year = "1991",
month = "6",
day = "15",
doi = "10.1016/0049-3848(91)90370-C",
language = "English",
volume = "62",
pages = "663--672",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers

AU - Tripodi, A.

AU - Moia, M.

AU - Bottasso, B.

AU - Tenconi, P. M.

AU - Gianese, F.

AU - Mannucci, P. M.

PY - 1991/6/15

Y1 - 1991/6/15

N2 - Eight healthy volunteers were given single subcutaneous doses of dermatan sulfate (DS, 100, 200 and 400 mg), heparin (5,000 IU) and placebo in random order. Wash-out between treatments was > 10 days. Serial blood samples were taken before and up to 24 hours after treatment to measure coagulation and fibrinolytic parameters. Thrombin generation was significantly inhibited by DS and heparin as compared to placebo. The effect of DS was dose-dependent. Peak inhibition after 200 mg DS was comparable to that of 5,000 IU heparin, but lasted longer. A small, bordeline significant prolongation of APTT was observed after 400 mg DS and heparin. The changes in PAI and fibrinolytic activities were those of the circadian variation. No changes were seen in the other parameters tested. In conclusion, single s.c. doses of DS (200, or 400 mg) inhibit ex vivo thrombin generation equally or more than 5,000 IU heparin and for a longer time. The effect of both treatments on fibrinolysis is negligible.

AB - Eight healthy volunteers were given single subcutaneous doses of dermatan sulfate (DS, 100, 200 and 400 mg), heparin (5,000 IU) and placebo in random order. Wash-out between treatments was > 10 days. Serial blood samples were taken before and up to 24 hours after treatment to measure coagulation and fibrinolytic parameters. Thrombin generation was significantly inhibited by DS and heparin as compared to placebo. The effect of DS was dose-dependent. Peak inhibition after 200 mg DS was comparable to that of 5,000 IU heparin, but lasted longer. A small, bordeline significant prolongation of APTT was observed after 400 mg DS and heparin. The changes in PAI and fibrinolytic activities were those of the circadian variation. No changes were seen in the other parameters tested. In conclusion, single s.c. doses of DS (200, or 400 mg) inhibit ex vivo thrombin generation equally or more than 5,000 IU heparin and for a longer time. The effect of both treatments on fibrinolysis is negligible.

KW - coagulation

KW - Dermatan sulfate

KW - fibrinolysis

KW - heparin

KW - pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=0025847760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025847760&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(91)90370-C

DO - 10.1016/0049-3848(91)90370-C

M3 - Article

C2 - 1926059

AN - SCOPUS:0025847760

VL - 62

SP - 663

EP - 672

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -